Orthofix Medical Inc. (OFIX) Target Reduced at Canaccord Following Q4 Results and 2026 Outlook Update

Orthofix Medical Inc. (NASDAQ:OFIX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.

Orthofix Medical Inc. (NASDAQ:OFIX) is given the tenth position on our list of small-cap stocks.

TheFly reported on February 26 that Canaccord reduced its price target for OFIX from $24 to $20 and gave it a Buy rating. The modification comes after the company updated its financial model to reflect the fourth-quarter performance and its outlook for 2026.

On February 24, Orthofix Medical Inc. (NASDAQ:OFIX) published its 2026 outlook. The company projects adjusted EBITDA to be between $95 million and $98 million, and it expects positive free cash flow for the whole year. This does not include any potential outcomes of a court settlement. The management has said that increasing commercial execution, increasing market penetration, and promoting broader use of enabling technologies such as 7D FLASH Navigation are priorities for 2026.

The company expects full-year revenue contributions from the TRUELOK Elevate System and the FITBONE Bone Transport and Trochanteric Lengthening Nails, in addition to the scheduled full launch of VIRATA in the second part of the year. Simplifying the Spine commercial channel, expanding the Biologics offering, and maintaining development throughout Limb Reconstruction and BGT operations are other areas of concentration. According to the leadership, these programs should assist in maintaining consistent revenue growth, enhancing margins, and boosting cash flow in 2026.

Orthofix Medical Inc. (NASDAQ:OFIX) is a global medical device company focused on spine and orthopedic solutions. It develops and markets implants, biologics, and bone growth therapies to support musculoskeletal healing and improve patient mobility and recovery outcomes.

While we acknowledge the potential of OFIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best GARP Stocks to Buy According to Analysts and 14 Best Affordable Dividend Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.